Cargando…

Oxybutynin and Tolterodine in a Trial for Treatment of Overactive Bladder in Iranian Women

OBJECTIVE: To evaluate the efficacy and side effects of Oxybutinin in comparison to tolterodine in treatment of overactive bladder (OAB) with detrussor overactivity (DOA) in Iranian women. MATERIALS AND METHODS: One hundred Iranian old women with clinical symptoms of OAB who show IDO in the filling...

Descripción completa

Detalles Bibliográficos
Autores principales: Aziminekoo, Elham, Ghanbari, Zinat, Hashemi, Shahrzad, Nemati, Maryam, Haghollahi, Fedyeh, Shokuhi, Nasim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064768/
https://www.ncbi.nlm.nih.gov/pubmed/24971138
_version_ 1782321987889135616
author Aziminekoo, Elham
Ghanbari, Zinat
Hashemi, Shahrzad
Nemati, Maryam
Haghollahi, Fedyeh
Shokuhi, Nasim
author_facet Aziminekoo, Elham
Ghanbari, Zinat
Hashemi, Shahrzad
Nemati, Maryam
Haghollahi, Fedyeh
Shokuhi, Nasim
author_sort Aziminekoo, Elham
collection PubMed
description OBJECTIVE: To evaluate the efficacy and side effects of Oxybutinin in comparison to tolterodine in treatment of overactive bladder (OAB) with detrussor overactivity (DOA) in Iranian women. MATERIALS AND METHODS: One hundred Iranian old women with clinical symptoms of OAB who show IDO in the filling cystometry participated in this randomized double-blinded parallel-group by using two kinds of the drugs for 4- week course (2 mg tolterodine twice-daily, or oxybutinin 5 mg, three times a day) in alike packages. We collected data from 3-day FVC before and after the treatment course. The effectiveness of each drug was studied using the paired t-test and improvement after treatment between two groups was compared by independent T-test. RESULTS: Positive changes in urinary urgency, Frequency and Urge incontinence after treatment in both groups were seen but mean improvements in the all were larger in the patients who treated by oxybutinin especially in terms of urgency and Urge incontinence. Dry mouth was the most common side-effect in two groups. Unlike other studies it was higher in the tolterodine group but the difference was not significant. CONCLUSION: Four week treatment with oxybutinin was better than tolterodine in improving urgency and urge incontinence but there were not statistically significance between them.
format Online
Article
Text
id pubmed-4064768
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-40647682014-06-26 Oxybutynin and Tolterodine in a Trial for Treatment of Overactive Bladder in Iranian Women Aziminekoo, Elham Ghanbari, Zinat Hashemi, Shahrzad Nemati, Maryam Haghollahi, Fedyeh Shokuhi, Nasim J Family Reprod Health Original Article OBJECTIVE: To evaluate the efficacy and side effects of Oxybutinin in comparison to tolterodine in treatment of overactive bladder (OAB) with detrussor overactivity (DOA) in Iranian women. MATERIALS AND METHODS: One hundred Iranian old women with clinical symptoms of OAB who show IDO in the filling cystometry participated in this randomized double-blinded parallel-group by using two kinds of the drugs for 4- week course (2 mg tolterodine twice-daily, or oxybutinin 5 mg, three times a day) in alike packages. We collected data from 3-day FVC before and after the treatment course. The effectiveness of each drug was studied using the paired t-test and improvement after treatment between two groups was compared by independent T-test. RESULTS: Positive changes in urinary urgency, Frequency and Urge incontinence after treatment in both groups were seen but mean improvements in the all were larger in the patients who treated by oxybutinin especially in terms of urgency and Urge incontinence. Dry mouth was the most common side-effect in two groups. Unlike other studies it was higher in the tolterodine group but the difference was not significant. CONCLUSION: Four week treatment with oxybutinin was better than tolterodine in improving urgency and urge incontinence but there were not statistically significance between them. Tehran University of Medical Sciences 2014-06 /pmc/articles/PMC4064768/ /pubmed/24971138 Text en Copyright © Vali-e-Asr Reproductive Health Research Center, Tehran University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Original Article
Aziminekoo, Elham
Ghanbari, Zinat
Hashemi, Shahrzad
Nemati, Maryam
Haghollahi, Fedyeh
Shokuhi, Nasim
Oxybutynin and Tolterodine in a Trial for Treatment of Overactive Bladder in Iranian Women
title Oxybutynin and Tolterodine in a Trial for Treatment of Overactive Bladder in Iranian Women
title_full Oxybutynin and Tolterodine in a Trial for Treatment of Overactive Bladder in Iranian Women
title_fullStr Oxybutynin and Tolterodine in a Trial for Treatment of Overactive Bladder in Iranian Women
title_full_unstemmed Oxybutynin and Tolterodine in a Trial for Treatment of Overactive Bladder in Iranian Women
title_short Oxybutynin and Tolterodine in a Trial for Treatment of Overactive Bladder in Iranian Women
title_sort oxybutynin and tolterodine in a trial for treatment of overactive bladder in iranian women
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064768/
https://www.ncbi.nlm.nih.gov/pubmed/24971138
work_keys_str_mv AT aziminekooelham oxybutyninandtolterodineinatrialfortreatmentofoveractivebladderiniranianwomen
AT ghanbarizinat oxybutyninandtolterodineinatrialfortreatmentofoveractivebladderiniranianwomen
AT hashemishahrzad oxybutyninandtolterodineinatrialfortreatmentofoveractivebladderiniranianwomen
AT nematimaryam oxybutyninandtolterodineinatrialfortreatmentofoveractivebladderiniranianwomen
AT haghollahifedyeh oxybutyninandtolterodineinatrialfortreatmentofoveractivebladderiniranianwomen
AT shokuhinasim oxybutyninandtolterodineinatrialfortreatmentofoveractivebladderiniranianwomen